Amgen vs Thermo Fisher Scientific at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | AMGN | TMO |
|---|---|---|
| Market cap | $241.45B | $233.04B |
| Price | $442.24 | $628.15 |
| P/E ratio (TTM) | 22.89 | 32.4 |
| P/B ratio (MRQ) | 20.38 | 4.09 |
| P/S ratio (TTM) | 4.8 | 4.9 |
| Revenue growth (1Y) | 9.92% | 3.91% |
| Return on equity (TTM) | 89.06% | 12.61% |
| Return on invested capital (TTM) | 14.50% | 8.06% |
| Gross margin (TTM) | 72.65% | 40.37% |
| Net margin (TTM) | 22.93% | 15.06% |
| Dividend yield (TTM) | 2.27% | 0.30% |
How they differ
Amgen is the larger company at $241.45B versus $233.04B, making them close in size.
On trailing earnings, Amgen is the cheaper of the two at 22.89 against 32.4 for Thermo Fisher Scientific.
On sales, Amgen is the cheaper of the two at 4.8 against 4.9 for Thermo Fisher Scientific.
Amgen leads on revenue growth over the past year, 9.92% against 3.91%.
Amgen leads on return on invested capital, 14.50% against 8.06%.
Amgen leads on gross margin, 72.65% against 40.37%.
Amgen offers the higher yield at 2.27% against 0.30%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Amgen or Thermo Fisher Scientific.